Affordability options with the Amneal PATHways® Patient Support Program

The Amneal PATHways® Patient Support Program makes accessing and paying for medicine seamless

The Amneal PATHways® Patient Support Program offers services such as:

  • Benefits investigation
  • Prior authorization support
  • Affordability options
  • Claims assistance
  • Co-pay assistance
Visit the PATHways Provider Portal to learn more.

The Amneal PATHways® Patient Support Program offers comprehensive support during every phase of treatment

Enrollment includes connection to Patient Access Specialists who will:

  • Explain benefits and insurance coverage
  • Discuss eligibility for affordability options
  • Inform about program updates as they occur

The Amneal PATHways® Co-pay Assistance Card is available to eligible patients

The Amneal PATHways®
Co-pay Assistance Card

Eligible* commercially insured patients may pay as little as $0 per treatment with an Amneal product.

*Eligibility conditions apply. Please contact your Patient Access Specialist for more information.

LEARN MORE

Scan the QR code to enroll in the Amneal PATHways® program, and see what affordability options you may be eligible for.

Questions? Call 1-866-4-AMNEAL (1-866-426-6325) with any questions or concerns Monday-Friday, 8:00 AM-8:00 PM ET.

Questions? Call 1-866-4-AMNEAL (1-866-426-6325) with any questions or concerns Monday-Friday, 8:00 AM-8:00 PM ET.

INDICATIONS

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

PEMRYDI RTU® is a folate analog metabolic inhibitor indicated:

  • in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
  • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous NSCLC.
  • as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • as a single agent for the treatment of patients with recurrent metastatic non-squamous NSCLC after prior chemotherapy.

Limitations of Use:
PEMRYDI RTU® is not indicated for treatment of squamous cell non-small cell lung cancer.

Mesothelioma

PEMRYDI RTU® is indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

IMPORTANT SAFETY INFORMATION

Contraindication

PEMRYDI RTU® is contraindicated in patients with a history of hypersensitivity reaction to pemetrexed.

Warnings and Precautions

  • Myelosuppression: PEMRYDI RTU® may cause severe bone marrow suppression resulting in cytopenia and an increased risk of infection. Do not administer when the absolute neutrophil count is less than 1500 cells/mm3 and platelets are less than 100,000 cells/mm3. Initiate supplementation with oral folic acid and intramuscular vitamin B12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMRYDI RTU®.
  • Renal Failure: PEMRYDI RTU® may cause severe and sometimes fatal renal failure. Do not administer when creatinine clearance is less than 45 mL/min.
  • Bullous and Exfoliative Skin Toxicity: Permanently discontinue PEMRYDI RTU® for severe and life-threatening bullous, blistering, or exfoliating skin toxicity.
  • Interstitial Pneumonitis: Withhold PEMRYDI RTU® for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation. If pneumonitis is confirmed, permanently discontinue PEMRYDI RTU®.
  • Radiation Recall: May occur in patients who received radiation weeks to years previously; permanently discontinue PEMRYDI RTU® for signs of radiation recall.
  • Embryo-Fetal Toxicity: PEMRYDI RTU® can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

  • The most common adverse reactions (incidence ≥ 20%) of PEMRYDI RTU® when administered as a single agent are fatigue, nausea, and anorexia.
  • The most common adverse reactions (incidence ≥ 20%) of PEMRYDI RTU® when administered with cisplatin are vomiting, neutropenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation.
  • The most common adverse reactions (incidence ≥ 20%) of PEMRYDI RTU® when administered with pembrolizumab and platinum chemotherapy are fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, and pyrexia.

Drug Interactions

  • Ibuprofen increased the risk of PEMRYDI RTU® toxicity in patients with mild to moderate renal impairment. Modify the ibuprofen dosage for patients with a creatinine clearance between 45 mL/min and 79 mL/min.

Use in Specific Populations

  • Lactation: Advise not to breastfeed.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Biosciences, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see accompanying full Prescribing Information.

ABOUT PEMRYDI RTU®

PRODUCT INFORMATION & DOSING

REIMBURSEMENT & SUPPORT

RESOURCES

CONTACT US

The content on this site is intended for pharmacy directors and healthcare professionals. Patients may be interested in the patient reimbursement and support information found in the Reimbursement & Support and Resources sections.

© 2025 Amneal Pharmaceuticals LLC. All rights reserved.
PP-PEM-US-0003   06/25

Linkedin X-twitter Youtube

INDICATIONS

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

PEMRYDI RTU® is indicated:

Contact Amneal

Thank you for your interest. Please fill out the form and allow us up to 72 hours to respond.

By supplying the information above and submitting this form, you are consenting to receive communications from Amneal.

ABOUT PEMRYDI RTU®

PRODUCT INFORMATION & DOSING

REIMBURSEMENT & SUPPORT

RESOURCES

Linkedin X-twitter Youtube

Thank you for reaching out. We’ll be in touch soon.